Basar Sirmagul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Basar Sirmagul has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Ugur Yalcin
Department of Nephrology, Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publication - Dilek Burukoğlu Dönmez
Department of Histology and Embryology, Eskişehir Osmangazi University, Eskişehir 26040, Turkey
1 shared publication - Engin Yildirim
Pharmacology Department,Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey
1 shared publication - Ertugrul Colak
Department of Biostatistics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey
1 shared publication F. Ozdener
Osmangazi University Medical School
1 shared publication- Fatma Sultan Kilic
ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication
Latest Publications
- 3 August 2011
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 12 (1) , 46-55
Effects of Everolimus in Combination with Sildenafil in Monocrotaline-induced Pulmonary Hypertension in Rats
- 3 August 2011
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 12 (1) , 46-55
Effects of Everolimus in Combination with Sildenafil in Monocrotaline-induced Pulmonary Hypertension in Rats
- 29 April 2009
- Published by Springer Nature in International Urology and Nephrology
- Vol. 41 (4) , 989-996
Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients
In patients with end-stage renal disease (ESRD), the 25-hydroxyvitamin D3 (25(OH)D3) level is known to be lower compared to that of the normal population. In the present study, we evaluated the influences of dialysis methods on the serum 25(OH)D3 level in patients with ESRD who are treated with hemodialysis and peritoneal dialysis. Thirty-nine peritoneal dialysis (PD), 49 hemodialysis (HD) patients, and 33 healthy controls were included in the present study. The mean HD period was 30.38 ± 21.81 months and the mean PD period was 26.35 ± 24.04 months. Serum samples from the HD and PD patients and healthy controls were examined in terms of 25(OH)D3, intact parathyroid hormone (iPTH), and other biochemical laboratory tests. Additionally, the 25(OH)D3 level in the peritoneal fluid was analyzed in the PD group. The mean 25(OH)D3 levels in the control, HD, and PD groups were 26.63 ± 10.89, 21.65 ± 12.38, and 13.46 ± 9.41 nmol/l, respectively (P < 0.001). The mean peritoneal fluid 25(OH)D3 level was 28.53 ± 7.66 nmol/l. Moreover, blood and PD fluid 25(OH)D3 levels were 34 compared in the PD group. The 25(OH)D3 level in dialysate was higher than that of serum in PD patients (P < 0.001). The significantly lower blood levels of 25(OH)D3 in PD patients compared to those of HD patients were thought to be due to 25(OH)D3 loss via peritoneal fluid.
- 29 April 2009
- Published by Springer Nature in International Urology and Nephrology
- Vol. 41 (4) , 989-996
Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients
In patients with end-stage renal disease (ESRD), the 25-hydroxyvitamin D3 (25(OH)D3) level is known to be lower compared to that of the normal population. In the present study, we evaluated the influences of dialysis methods on the serum 25(OH)D3 level in patients with ESRD who are treated with hemodialysis and peritoneal dialysis. Thirty-nine peritoneal dialysis (PD), 49 hemodialysis (HD) patients, and 33 healthy controls were included in the present study. The mean HD period was 30.38 ± 21.81 months and the mean PD period was 26.35 ± 24.04 months. Serum samples from the HD and PD patients and healthy controls were examined in terms of 25(OH)D3, intact parathyroid hormone (iPTH), and other biochemical laboratory tests. Additionally, the 25(OH)D3 level in the peritoneal fluid was analyzed in the PD group. The mean 25(OH)D3 levels in the control, HD, and PD groups were 26.63 ± 10.89, 21.65 ± 12.38, and 13.46 ± 9.41 nmol/l, respectively (P < 0.001). The mean peritoneal fluid 25(OH)D3 level was 28.53 ± 7.66 nmol/l. Moreover, blood and PD fluid 25(OH)D3 levels were 34 compared in the PD group. The 25(OH)D3 level in dialysate was higher than that of serum in PD patients (P < 0.001). The significantly lower blood levels of 25(OH)D3 in PD patients compared to those of HD patients were thought to be due to 25(OH)D3 loss via peritoneal fluid.
- 1 December 2007
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 7 (4) , 142-148
Calcium channel blockers increase the amount of nitrite production in rabbits without decreasing the responsiveness of platelets to collagen
By virtue of their ability to increase nitric oxide (NO) production, it is thought that calcium channel blockers (CCBs) may be involved in the inhibition of platelet aggregation. In an attempt to compare the abilities of different groups of calcium antagonists to affect NO generation and platelet aggregation, single doses of the calcium antagonists verapamil, nicardipine and diltiazem were administered to rabbits. It was found that each of these drugs increased the levels of nitrite significantly. It was also found that these drugs had different time courses of action. Of the CCBs used in this study, verapamil was found to induce the greatest increase in nitrite production (about a 4-fold increase over basal levels), peaking at 90 min (PPPP<0.001). Blood samples taken from the animals were analysed using whole-blood aggregometry in order to assess the amount of collagen-induced platelet aggregation. At the time point when NO release was expected to be maximal (150 min), it was found that the collagen-induced platelet responses were not significantly altered in platelets from rabbits that had been treated with either verapamil or nicardipine. In contrast, at the 150-min time point, diltiazem treatment made the platelets hypersensitive to collagen stimulation. The results of this study demonstrate that treatment with calcium channel antagonists increases the levels of NO produced in rabbits, however, this increase in NO production is not accompanied by a decrease in the reactivity of platelets to collagen.
- 1 December 2007
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 7 (4) , 142-148
Calcium channel blockers increase the amount of nitrite production in rabbits without decreasing the responsiveness of platelets to collagen
By virtue of their ability to increase nitric oxide (NO) production, it is thought that calcium channel blockers (CCBs) may be involved in the inhibition of platelet aggregation. In an attempt to compare the abilities of different groups of calcium antagonists to affect NO generation and platelet aggregation, single doses of the calcium antagonists verapamil, nicardipine and diltiazem were administered to rabbits. It was found that each of these drugs increased the levels of nitrite significantly. It was also found that these drugs had different time courses of action. Of the CCBs used in this study, verapamil was found to induce the greatest increase in nitrite production (about a 4-fold increase over basal levels), peaking at 90 min (PPPP<0.001). Blood samples taken from the animals were analysed using whole-blood aggregometry in order to assess the amount of collagen-induced platelet aggregation. At the time point when NO release was expected to be maximal (150 min), it was found that the collagen-induced platelet responses were not significantly altered in platelets from rabbits that had been treated with either verapamil or nicardipine. In contrast, at the 150-min time point, diltiazem treatment made the platelets hypersensitive to collagen stimulation. The results of this study demonstrate that treatment with calcium channel antagonists increases the levels of NO produced in rabbits, however, this increase in NO production is not accompanied by a decrease in the reactivity of platelets to collagen.
- 30 March 2004
- Vol. 56 (1) , 137-41
Intestinal absorption of digoxin and interaction with nimodipine in rats.
It is known that digoxin, which is a liposoluble cardiac glycoside, is well absorbed from intestine. In the present study, the absorption rates of digoxin from rat duodenum and the proximal and terminal parts of small intestine were determined in vitro. The isolated everted duodenum and intestinal sacs were put into oxygenated Tyrode solution at 37 degrees C. The Tyrode solution on the outer, mucosal side of intestinal segments contained 0.3 microM digoxin. Samples from the internal serosal side of the intestinal sacs were taken at 30, 60 and 120 min after the start of the experiments. The concentration of digoxin in the samples of fluid were determined using a radioimmunoassay method. The effect of nimodipine (0.1 and 0.2 mM) on digoxin absorption was also evaluated on the terminal segment of rat intestine. The interaction of nimodipine (0.5 mg/kg) and digoxin (0.2 mg/kg) was investigated in vivo when they were given perorally to rats. The duodenal absorption of digoxin was lower than in the small intestine. The highest absorption occurred in the terminal segment of the small intestine. Nimodipine increased the absorption of digoxin from the terminal segment of intestine in vitro, while it did not affect the serum digoxin concentration in vivo.
- 30 March 2004
- Vol. 56 (1) , 137-41
Intestinal absorption of digoxin and interaction with nimodipine in rats.
It is known that digoxin, which is a liposoluble cardiac glycoside, is well absorbed from intestine. In the present study, the absorption rates of digoxin from rat duodenum and the proximal and terminal parts of small intestine were determined in vitro. The isolated everted duodenum and intestinal sacs were put into oxygenated Tyrode solution at 37 degrees C. The Tyrode solution on the outer, mucosal side of intestinal segments contained 0.3 microM digoxin. Samples from the internal serosal side of the intestinal sacs were taken at 30, 60 and 120 min after the start of the experiments. The concentration of digoxin in the samples of fluid were determined using a radioimmunoassay method. The effect of nimodipine (0.1 and 0.2 mM) on digoxin absorption was also evaluated on the terminal segment of rat intestine. The interaction of nimodipine (0.5 mg/kg) and digoxin (0.2 mg/kg) was investigated in vivo when they were given perorally to rats. The duodenal absorption of digoxin was lower than in the small intestine. The highest absorption occurred in the terminal segment of the small intestine. Nimodipine increased the absorption of digoxin from the terminal segment of intestine in vitro, while it did not affect the serum digoxin concentration in vivo.